MAM
Motorola dials up marketing game, appoints Gagandeep Bedi to lead India brand blitz
MUMBAI: Motorola just hit the speed dial on its India playbook. On 4 March 2025, the company announced Gagandeep Bedi as its new head of marketing for Motorola Mobility India. And let’s just say, this hire isn’t a soft launch—it’s a statement.
Reporting to Motorola Asia Pacific head of marketing Shivam Ranjan, Bedi will lead the brand’s marketing orchestra across the Indian terrain—where the smartphone war isn’t fought with specs alone, but with story, swagger and smart strategy.
“I am thrilled to join Motorola at such an exciting time in its growth journey. Motorola is an iconic brand with a strong legacy of innovation, and I look forward to leveraging my experience to further strengthen its market presence in India,” said Bedi. “With a rapidly evolving consumer landscape, I am eager to drive impactful marketing strategies, enhance brand engagement, and contribute to the brand’s continued success in the country.”
Bedi comes equipped with a 17-year track record across top-tier names—Infinix, Tecno, Beetel, Reliance Jio, Samsung and Bharti Retail—where he’s launched and scaled brands, cracked GTM strategies, and helmed show-stopping product rollouts. From telcos to tech, his marketing toolkit’s seen more action than a flagship launch day.
“As we continue to expand our presence in India, I am excited to welcome Gagandeep Bedi to the team,” said Ranjan. “India is a key growth market for us in Asia Pacific and we are committed to grow aspiration and desire for our brand in the market.”
And it’s not just corporate optimism talking. Over the past two years, Motorola has seen double-digit premium-to-market growth and triple-digit YoY growth over the last three quarters. That’s not just momentum—it’s a market mood swing.
As Motorola revs up its innovation engine and sharpens its brand voice, Bedi’s entry could be the high-impact, high-decibel move the brand needs to dominate India’s hyper-competitive smartphone space.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
